February 22, 2007 – In a European trial, Avastin increased the progression-free survival of patients with non-small cell lung cancer. But the results included an unexpected kicker: Avastin was just as effective at the low dose as one that was twice as strong. The low dose cuts the revenues from the drug (for this indication) in half. Genentech and its partner Roche both fell on the news, with Genentech dropping 3%. We look at the numbers...
